Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited has announced the opening of the first pediatric site in Mexico for the ACTION3 Phase 3 clinical trial, targeting recruitment of patients aged 12-17 with FSGS, a kidney disease. An additional 14 sites across the Americas and UK will join the effort, with recruitment on-track for a mid-2025 interim analysis. The company’s strong financial position, supported by cash reserves and anticipated incentives, underpins the ongoing study, which is further bolstered by the appointment of renowned pediatric nephrologist Dr. Howard Trachtman to the Medical Advisory Board.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.
